AGER and prostate cancer: In fact, many previous studies have demonstrated the over-expression of HMGB1 with its receptor, receptor for advanced glycation end products (RAGE), in different tumor types, including breast carcinoma [7], colorectal cancer [8], prostate cancer [9], pancreatic cancer [10], and hepatocellular carcinoma [11].